| The ICARUS project : study protocol for a randomised controlled trial Investigating aCute heArt failuRe decongestion guided by lung UltraSonography | Trials |  | | 2026 | 14 | 93 |
|
| Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants | Frontiers in pharmacology | | | 2026 | 12 | 20 |
|
| Cytochrome P450 phenotyping using the Geneva cocktail improves metabolic capacity prediction in a hospitalized patient population | British journal of clinical pharmacology |  | | 2025 | 52 | 0 |
|
| Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling | Clinical pharmacokinetics | | | 2025 | 71 | 170 |
|
| Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban | British journal of clinical pharmacology | | | 2025 | 88 | 1 |
|
| Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serum | European journal of neuroscience | | | 2024 | 89 | 248 |
|
| Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side | CPT: pharmacometrics & systems pharmacology | | | 2023 | 149 | 544 |
|
| Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study | CPT: pharmacometrics & systems pharmacology | | | 2023 | 137 | 481 |
|
| Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial | Clinical and translational science | | | 2022 | 160 | 194 |
|
| Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting | Journal of personalized medicine | | | 2022 | 228 | 419 |
|
| Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities | Clinical pharmacology and therapeutics | | | 2022 | 183 | 394 |
|
| Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients | Acta Physiologica | | | 2021 | 403 | 3 |
|
